|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.22 USD | +0.98% |
|
+2.46% | +28.18% |
| Dec. 03 | Pacira Biosciences reports inducement grants under Nasdaq Listing Rule | RE |
| Dec. 02 | Pacira Says Iovera Outperformed Radiofrequency Ablation in Chronic Low Back Pain | MT |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Revenues | 430M | 542M | 667M | 675M | 701M | |||||
Total Revenues | 430M | 542M | 667M | 675M | 701M | |||||
Cost of Goods Sold, Total | 177M | 196M | 274M | 261M | 252M | |||||
Gross Profit | 253M | 346M | 393M | 414M | 449M | |||||
Selling General & Admin Expenses, Total | 194M | 199M | 255M | 269M | 294M | |||||
Amortization of Goodwill and Intangible Assets - (IS) | 7.87M | 13.55M | 57.29M | 57.29M | 57.29M | |||||
Other Operating Expenses, Total | 201M | 213M | 312M | 327M | 351M | |||||
Operating Income | 51.52M | 133M | 81.43M | 87.32M | 97.57M | |||||
Interest Expense, Total | -25.67M | -31.75M | -39.98M | -20.31M | -16.57M | |||||
Interest And Investment Income | 4.63M | 896K | 4.54M | 11.44M | 19.69M | |||||
Net Interest Expenses | -21.04M | -30.85M | -35.43M | -8.86M | 3.12M | |||||
Currency Exchange Gains (Loss) | - | - | - | - | - | |||||
Other Non Operating Income (Expenses) | 1.23M | 7K | -1.2M | -186K | -373K | |||||
EBT, Excl. Unusual Items | 31.71M | 102M | 44.8M | 78.28M | 100M | |||||
Restructuring Charges | 188K | - | - | -1.11M | -8.53M | |||||
Merger & Related Restructuring Charges | -150K | -40.9M | -11.24M | -1.96M | -1.46M | |||||
Impairment of Goodwill | - | - | - | - | -163M | |||||
Gain (Loss) On Sale Of Investments | 1.62M | -2.67M | -10.09M | - | - | |||||
Asset Writedown | - | - | -36.63M | - | - | |||||
Legal Settlements | - | - | - | - | - | |||||
Other Unusual Items | -13.28M | -2.01M | 26.48M | -13.5M | 9.81M | |||||
EBT, Incl. Unusual Items | 20.09M | 56.4M | 13.3M | 61.7M | -63.11M | |||||
Income Tax Expense | -125M | 14.42M | -2.61M | 19.75M | 36.45M | |||||
Earnings From Continuing Operations | 146M | 41.98M | 15.91M | 41.96M | -99.56M | |||||
Net Income to Company | 146M | 41.98M | 15.91M | 41.96M | -99.56M | |||||
Net Income - (IS) | 146M | 41.98M | 15.91M | 41.96M | -99.56M | |||||
Net Income to Common Incl Extra Items | 146M | 41.98M | 15.91M | 41.96M | -99.56M | |||||
Net Income to Common Excl. Extra Items | 146M | 41.98M | 15.91M | 41.96M | -99.56M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | 3.41 | 0.95 | 0.35 | 0.91 | -2.15 | |||||
Basic EPS - Continuing Operations | 3.41 | 0.95 | 0.35 | 0.91 | -2.15 | |||||
Basic Weighted Average Shares Outstanding | 42.67M | 44.26M | 45.52M | 46.22M | 46.24M | |||||
Net EPS - Diluted | 3.33 | 0.92 | 0.34 | 0.89 | -2.15 | |||||
Diluted EPS - Continuing Operations | 3.33 | 0.92 | 0.34 | 0.89 | -2.15 | |||||
Diluted Weighted Average Shares Outstanding | 43.68M | 45.63M | 46.54M | 51.98M | 46.24M | |||||
Normalized Basic EPS | 0.46 | 1.44 | 0.62 | 1.06 | 1.36 | |||||
Normalized Diluted EPS | 0.45 | 1.4 | 0.6 | 0.94 | 1.36 | |||||
Supplemental Items | ||||||||||
EBITDA | 71.42M | 161M | 162M | 163M | 176M | |||||
EBITA | 59.38M | 146M | 139M | 145M | 155M | |||||
EBIT | 51.52M | 133M | 81.43M | 87.32M | 97.57M | |||||
EBITDAR | 83.58M | 175M | 178M | 179M | 192M | |||||
Total Revenues (As Reported) | 430M | 542M | 667M | 675M | 701M | |||||
Effective Tax Rate - (Ratio) | -624.39 | 25.57 | -19.6 | 32 | -57.77 | |||||
Current Domestic Taxes | 1.18M | 3.53M | 5.31M | 4.13M | 15.82M | |||||
Current Foreign Taxes | - | 19K | 29K | 1K | 11K | |||||
Total Current Taxes | 1.18M | 3.55M | 5.34M | 4.13M | 15.83M | |||||
Deferred Domestic Taxes | -127M | 10.87M | -7.94M | 15.62M | 20.62M | |||||
Total Deferred Taxes | -127M | 10.87M | -7.94M | 15.62M | 20.62M | |||||
Normalized Net Income | 19.82M | 63.74M | 28M | 48.92M | 62.7M | |||||
Interest Capitalized | 2.4M | 3.9M | 4.1M | 3.5M | 2.1M | |||||
Interest on Long-Term Debt | 28.06M | 35.66M | 44.09M | 23.83M | 18.67M | |||||
Supplemental Operating Expense Items | ||||||||||
Research And Development Expense From Footnotes | 59.42M | 55.54M | 111M | 76.26M | 81.58M | |||||
Net Rental Expense, Total | 12.15M | 13.7M | 15.68M | 15.64M | 15.46M | |||||
Imputed Operating Lease Interest Expense | 6.11M | 4.68M | 5.85M | 4.41M | 3.77M | |||||
Imputed Operating Lease Depreciation | 6.04M | 9.02M | 9.84M | 11.22M | 11.69M | |||||
Stock-Based Comp., COGS (Total) | 10.8M | 11.36M | 12.56M | 14.23M | 12.71M | |||||
Stock-Based Comp., SG&A Exp. (Total) | 29.12M | 30.89M | 35.53M | 33.66M | 34.86M | |||||
Stock-Based Comp., Other (Total) | - | - | - | - | 3.6M | |||||
Total Stock-Based Compensation | 39.92M | 42.25M | 48.09M | 47.9M | 51.17M |
- Stock Market
- Equities
- PCRX Stock
- Financials Pacira BioSciences, Inc.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















